Compare LOPE & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOPE | TGTX |
|---|---|---|
| Founded | 1949 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.9B |
| IPO Year | 2008 | 2008 |
| Metric | LOPE | TGTX |
|---|---|---|
| Price | $163.54 | $28.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $220.00 | $49.80 |
| AVG Volume (30 Days) | 283.0K | ★ 1.5M |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 7.71 | 2.77 |
| Revenue | ★ $511,257,000.00 | $2,785,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.99 | $25.01 |
| P/E Ratio | $21.11 | ★ $10.38 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $149.37 | $25.37 |
| 52 Week High | $223.04 | $46.48 |
| Indicator | LOPE | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 46.17 |
| Support Level | $151.84 | $27.51 |
| Resistance Level | $168.28 | $32.77 |
| Average True Range (ATR) | 4.64 | 1.18 |
| MACD | 0.63 | -0.14 |
| Stochastic Oscillator | 67.36 | 38.84 |
Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges both online, on the ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.